These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31070273)

  • 1. Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells.
    Liolios C; Sachpekidis C; Schäfer M; Kopka K
    J Labelled Comp Radiopharm; 2019 Jun; 62(8):510-522. PubMed ID: 31070273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
    Eder M; Schäfer M; Bauder-Wüst U; Haberkorn U; Eisenhut M; Kopka K
    Prostate; 2014 May; 74(6):659-68. PubMed ID: 24464532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosynthesis and biological evaluation of 18F-labeled bispecific heterodimer targeted dual gastrin-releasing peptide receptor and prostate-specific membrane antigen for prostate cancer imaging.
    Ye S; Li H; Hu K; Li L; Zhong J; Yan Q; Wang Q
    Nucl Med Commun; 2022 Mar; 43(3):323-331. PubMed ID: 34919064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy.
    Rybalov M; Ananias HJ; Hoving HD; van der Poel HG; Rosati S; de Jong IJ
    Int J Mol Sci; 2014 Apr; 15(4):6046-61. PubMed ID: 24727373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors.
    Liolios C; Patsis C; Lambrinidis G; Tzortzini E; Roscher M; Bauder-Wüst U; Kolocouris A; Kopka K
    Mol Pharm; 2022 Jul; 19(7):2231-2247. PubMed ID: 35467350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer.
    Liolios C; Schäfer M; Haberkorn U; Eder M; Kopka K
    Bioconjug Chem; 2016 Mar; 27(3):737-51. PubMed ID: 26726823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
    Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    Iagaru A
    J Nucl Med; 2017 Dec; 58(12):1883-1884. PubMed ID: 28970333
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.
    Sonni I; Baratto L; Iagaru A
    PET Clin; 2017 Apr; 12(2):159-171. PubMed ID: 28267450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
    Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
    Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer.
    Stott Reynolds TJ; Smith CJ; Lewis MR
    Adv Exp Med Biol; 2018; 1096():135-158. PubMed ID: 30324352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of radiolabeled PSMA ligands for tumor imaging.
    Shahrokhi P; Masteri Farahani A; Tamaddondar M; Rezazadeh F
    Chem Biol Drug Des; 2022 Jan; 99(1):136-161. PubMed ID: 34472217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
    Haberkorn U; Eder M; Kopka K; Babich JW; Eisenhut M
    Clin Cancer Res; 2016 Jan; 22(1):9-15. PubMed ID: 26728408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.
    Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Kip A; Franssen GM; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Lütje S; Heskamp S
    Theranostics; 2021; 11(4):1527-1541. PubMed ID: 33408764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aspects of molecular imaging in prostate cancer.
    Ceci F; Castellucci P; Cerci JJ; Fanti S
    Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.